', 'pageview');
xfor-20221103
0001501697FALSE00015016972022-11-032022-11-03


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Data of earliest event reported): November 3, 2022
X4 PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         Delaware001-3829527-3181608
        (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
61 North Beacon Street,4th Floor
Boston,Massachusetts02134
(Address of principal executive offices)(Zip Code)

(857) 529-8300
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareXFORThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  







Item 2.02
Results of Operations and Financial Condition.
On November 3, 2022, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the third quarter ended September 30, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished under this Item 2.02 in this Current Report of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01Other Events.
Effective November 3, 2022, Mr. Mark S. Baldry was appointed as Chief Commercial Officer of the Company. A copy of the press release announcing this appointment is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

On November 3, 2022, the Company also announced that Dr. Diego Cadavid, its Chief Medical Officer, intends to resign by the end of 2022, and serve as a consultant thereafter. Dr. Cadavid is leaving to pursue an opportunity that closely aligns with his commitment to patients with intractable central nervous system disorders. The Company intends to appoint Dr. Murray Stewart, a member of the Company’s Board of Directors, as interim Chief Medical Officer, while the Company conducts a search for a permanent Chief Medical Officer. The Company expects to enter into definitive agreements with each of Dr. Cadavid and Dr. Stewart at a later date to formalize the terms of these arrangements.

Item 9.01Financial Statements and Exhibits.
Exhibit No.Description
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


X4 PHARMACEUTICALS, INC.
Date: November 3, 2022By:/s/ Adam Mostafa
Adam Mostafa
Chief Financial Officer


Document
Exhibit 99.1
https://cdn.kscope.io/4e8d7e6761ce9f7d13159ff122feb0b3-x4logo.jpg                                

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the fourth quarter of 2022

Conference call to be hosted today at 8:30 a.m. ET

BOSTON – November 3, 2022— X4 Pharmaceuticals Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent and upcoming expected milestones.

“This is a truly exciting time for X4 as we near the announcement of top-line data from our first pivotal clinical trial and continue to advance our lead candidate, mavorixafor, towards commercialization,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “Following our September release of positive data from the Phase 1b clinical trial of mavorixafor across a number of chronic neutropenic disorders, we now eagerly await the results from the 4WHIM registration trial. With no oral therapeutic approved for these patients, we believe mavorixafor, if approved, could represent a new opportunity to transform the treatment landscape and create a new standard of care for almost 50,000 underserved patients in the U.S.”

Recent Highlights & Anticipated Upcoming Milestones
In July, X4 completed a private investment in public equity (PIPE) financing, receiving aggregate gross proceeds of approximately $55 million; the financing included participation from new and existing investors.
In July, the company announced a strategic re-prioritization of resources towards advancing mavorixafor in chronic neutropenic disorder indications, including WHIM syndrome, while progressing oncology programs only upon completion of strategic partnership(s); the announced strategic update was also inclusive of cost-cutting initiatives estimated to extend X4’s cash runway into the third quarter of 2023.
In late September, X4 held an event highlighting new positive data from its Phase 1b clinical trial demonstrating the ability of mavorixafor to increase and normalize absolute neutrophil counts (ANC) in people with idiopathic, cyclic, or congenital chronic neutropenia (CN) as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF). The company believes that these results suggest an expanded market opportunity for mavorixafor that could include almost 50,000 additional diagnosed patients in the U.S.
The Phase 1b trial in chronic neutropenic disorders is currently being amended and expanded into a Phase 1b/Phase 2 clinical trial to assess the long-term durability, safety, and tolerability of mavorixafor in a larger patient population; X4 anticipates the amended trial to begin generating additional clinical data in the first half of 2023.


Exhibit 99.1
The company recently announced the appointment of industry veteran Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all pre-commercial and product launch efforts for mavorixafor as clinical development advances.
Following recent completion of the last patient/last visit in the company’s Phase 3 clinical trial of mavorixafor in WHIM syndrome (the 4WHIM trial), X4 continues to anticipate the announcement of top-line results from the trial in the fourth quarter of 2022 and the submission for U.S. regulatory approval of mavorixafor in WHIM early in the second half of 2023, if the data are positive.

X4 today also announced that its Chief Medical Officer, Dr. Diego Cadavid, intends to depart the company by the end of 2022, but will continue to support X4 as a consultant. Dr. Cadavid, still a practicing neurologist, is leaving to pursue an opportunity that closely aligns with his commitment to patients with intractable CNS disorders.

X4 is appointing Dr. Murray Stewart as interim Chief Medical Officer while it conducts a search for a permanent replacement for Dr. Cadavid. Dr. Stewart, who has served as a member of the X4 Board of Directors since March 2019, has had a distinguished career in the life sciences industry, including an 18-year tenure at GlaxoSmithKline (GSK), where he held multiple research and development leadership roles, including Chief Medical Officer, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Dr. Stewart also previously served as Chief Medical Officer of Rhythm Pharmaceuticals, leading the successful NDA submission and approval of ImcivreeTM (setmelanotide), an innovative treatment for rare causes of obesity.

Dr. Stewart commented: “I am very pleased to be able to support X4 through this exciting time, as we prepare to unblind the mavorixafor Phase 3 WHIM data and advance to an NDA submission if the data are positive. I look forward to partnering with the clinical and executive management teams to continue X4’s journey towards providing people with WHIM and other CN disorders with a potentially transformative new therapy.”

Third Quarter 2022 Financial Results
Cash, Cash Equivalents & Restricted Cash: X4 had $81.1 million in cash, cash equivalents, and restricted cash as of September 30, 2022. X4 believes that it has sufficient funds to support company operations into the third quarter of 2023.
Research and Development (R&D) Expenses were $14.1 million for the third quarter of 2022 as compared to $13.2 million for the comparable period in 2021. R&D expenses include $0.6 million and $0.6 million of certain non-cash expenses for the third quarter of 2022 and 2021, respectively.
Selling, General, and Administrative Expenses (SG&A) were $6.0 million for the third quarter of 2022 as compared to $5.9 million for the comparable period in 2021. SG&A expenses include $0.5 million and $0.9 million of certain non-cash expenses for the third quarter of 2022 and 2021, respectively.
Net Loss: X4 reported a net loss of $21.6 million for the third quarter of 2022, as compared to $20.2 million for the comparable period in 2021. Net losses include $1.1 million and $1.5 million of certain non-cash expenses for the third quarter of 2022 and 2021, respectively.
Conference Call and Webcast
X4 will host a conference call and webcast today at 8:30 am ET to discuss important upcoming milestones, including the pending release of results from the company’s Phase 3 trial of its lead candidate, mavorixafor, in the treatment of WHIM syndrome. The conference call can be accessed by dialing 1-855-327-6837 within the United States or 1-631-891-4304 internationally, followed by the


Exhibit 99.1
conference ID: 10020371. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay of the conference call will be available on the website.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the mobilization of white blood cells, we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of immune system diseases, including a range of chronic neutropenic disorders and certain types of cancer. The efficacy and safety of mavorixafor are being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, a rare, primary immunodeficiency disease typically caused by genetic mutations in the CXCR4 receptor gene. We are also studying mavorixafor in two Phase 1b clinical trials – one in patients with chronic neutropenic disorders including congenital, idiopathic, and cyclic neutropenia, and one concurrently with ibrutinib in patients with Waldenström’s macroglobulinemia (WM), a rare B-cell lymphoma. Further clinical development of mavorixafor in WM will now be subject to completing a strategic partnership as we focus our resources on advancing mavorixafor for the benefit of patients with chronic neutropenic disorders. We continue to leverage our insights into CXCR4 biology at our corporate headquarters in Boston, Massachusetts and at our research facility in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development of X4’s pipeline and its research and development programs, including the timing of the Phase 3 clinical trial of mavorixafor in WHIM syndrome and the Phase 1b trial in chronic neutropenic disorders; the anticipated reporting of data; interactions with regulators and the timing thereof, anticipated timing of submission for U.S. regulatory approval of mavorixafor in WHIM; expectations regarding the potential efficacy and commercial potential of mavorixafor; and expectations regarding X4’s cash runway. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, on account of uncertainties inherent in the initiation and completion of clinical trials and clinical development; the risk that trials and studies may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that the FDA may not support and accept a regulatory submission for mavorixafor, and X4’s interactions with the FDA may not have satisfactory outcomes; the risks related to X4’s ability to raise additional capital; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2022, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

(Tables to Follow)


Exhibit 99.1

X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Operating expenses:

Research and development $14,110 $13,188 42,044 38,485 
Selling, general and administrative 6,044 5,931 20,457 17,567 
Gain on sale of non-financial asset— — (509)— 
Total operating expenses20,154 19,119 61,992 56,052 
Loss from operations(20,154)(19,119)(61,992)(56,052)
Other expense, net(1,445)(1,054)(2,757)(2,423)
Loss before provision for income taxes(21,599)(20,173)(64,749)(58,475)
Provision for income taxes(13)14 14 
Net loss(21,586)(20,175)(64,763)(58,489)
Deemed dividend due to Class B warrant price reset(287)— (2,546)(8,239)
Net loss attributable to common stockholders$(21,873)$(20,175)$(67,309)$(66,728)
Net loss per share attributable to common stockholders- basic and diluted $(0.26)$(0.76)$(1.32)$(2.71)
Weighted average common shares outstanding-basic and diluted83,211 26,609 50,976 24,667 



X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Nine months ended September 30,
20222021
Net loss$(64,763)$(58,489)
Adjustments to reconcile net loss to net cash used in operating activities6,493 6,809 
Changes in operating assets and liabilities 261 (172)
Net cash used in operating activities (58,009)(51,852)
Net cash used in investing activities (69)(602)
Net cash provided by financing activities 56,586 49,675 
Impact of foreign exchange on cash, cash equivalents and restricted cash(468)(203)
Net decrease in cash, cash equivalents and restricted cash(1,960)(2,982)
Cash, cash equivalents and restricted cash at beginning of period83,108 80,702 
Cash, cash equivalents and restricted cash at end of period$81,148 $77,720 





Exhibit 99.1


X4 PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
September 30, 2022December 31, 2021
Current assets:
Cash and cash equivalents $79,855 $81,787 
Research and development incentive receivable909 747 
Prepaid expenses and other current assets4,954 5,344 
Total current assets85,718 87,878 
Property and equipment, net1,194 1,514 
Goodwill17,351 17,351 
Right-of-use assets7,606 8,710 
Other assets1,537 1,723 
Total assets$113,406 $117,176 
Current liabilities:
Accounts payable$3,800 $4,283 
Accrued expenses9,128 7,870 
Current portion of lease liability1,164 1,075 
Current portion of long-term debt14,621 795 
Total current liabilities28,713 14,023 
Long-term debt, including accretion, net of discount18,733 33,139 
Lease liabilities3,799 4,776 
Other liabilities312 826 
Total liabilities51,557 52,764 
Total stockholders' equity61,849 64,412 
Total liabilities and stockholders' equity$113,406 $117,176 

Contacts:

Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Cherilyn Cecchini, M.D. (media)
LifeSci Communications
ccecchini@lifescicomms.co


Document
Exhibit 99.2
https://cdn.kscope.io/4e8d7e6761ce9f7d13159ff122feb0b3-x4logoa.jpg                                

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022

BOSTON – October 26, 2022 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all pre-commercial and product launch efforts for the company’s lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome.

“We are thrilled that Mark has committed to join us at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “With more than 30 years of experience building high-performing commercial teams and developing effective global strategies to successfully launch new therapeutics into both rare disease and specialty markets, Mark is the perfect fit for the company as we continue to advance mavorixafor towards commercialization in multiple chronic neutropenic disorders.”

Mr. Baldry commented on his appointment: “This is a very exciting time to be joining X4, as they prepare to reveal Phase 3 data from the mavorixafor 4WHIM pivotal clinical trial. Throughout my career, I have been drawn to therapeutic areas where I believe novel candidates can have a significant impact on patients and their caregivers. Given the previously reported Phase 2 data in WHIM and the recently reported Phase 1b data in chronic neutropenia, I believe mavorixafor has the potential to not only become the first therapy for people with WHIM syndrome, but also to become a new standard of care for those with chronic neutropenic disorders who face considerable challenges with currently available therapies. I’m looking forward to working with the entire X4 team to help realize the potential of mavorixafor and make a real difference in people’s lives.”

Mr. Baldry’s previous roles include Chief Commercial Officer of Freeline Therapeutics Holdings, Chief Commercial Officer of Wave Life Sciences, and Vice President, Global Marketing and then Senior Vice President, Global Marketing & Commercial Operations at Amicus Therapeutics. In these roles, he was responsible for building and executing on global commercial strategies to support successful launches of innovative medicines in orphan diseases, including the first oral chaperone therapy for the treatment of Fabry disease. Throughout his earlier career, Mr. Baldry held multiple leadership positions at Biogen Inc., including Vice President, Public Affairs and Vice President, New Product Commercialization, and at the Human Genetic Therapies division of Shire Pharmaceuticals, where he served as Head of Global Strategic Marketing and Head of Marketing, Market Access and Public Affairs, Europe, Middle East, and Africa. Mr. Baldry received a BSc in Genetics from York University (U.K.) and an MBA from Concordia University (Canada).






Exhibit 99.2
About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system. Our lead clinical candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the mobilization of white blood cells, we believe that mavorixafor has the potential to provide therapeutic benefit across a wide variety of immune system diseases, including a range of chronic neutropenic disorders and certain types of cancer. The efficacy and safety of mavorixafor are being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, a rare, primary immunodeficiency disease typically caused by genetic mutations in the CXCR4 receptor gene. We are also studying mavorixafor in two Phase 1b clinical trials – one in patients with chronic neutropenic disorders including congenital, idiopathic, and cyclic neutropenia, and one concurrently with ibrutinib in patients with Waldenström’s macroglobulinemia (WM), a rare B-cell lymphoma. Further clinical development of mavorixafor in WM will now be subject to completing a strategic partnership as we focus our resources on advancing mavorixafor for the benefit of patients with chronic neutropenic disorders. We continue to leverage our insights into CXCR4 biology at our corporate headquarters in Boston, Massachusetts and at our research facility in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, on account of uncertainties inherent in the initiation and completion of clinical trials and clinical development; the risk that trials and studies may not have satisfactory outcomes; the risk that the outcomes of preclinical studies or earlier clinical trials will not be predictive of later clinical trial results; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; the potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risks related to X4’s ability to raise additional capital, and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2022, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

Contacts:
Daniel Ferry (investors)
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Cherilyn Cecchini, MD (media)
LifeSci Communications
ccecchini@lifescicomms.com